SCHEMBL342420

SCHEMBL342420

O=C(ON1C(=O)CCC1=O)c1ccc(CSSc2ccccn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
RAB9A P51151 6/20 0.41
ALDH1A1 P00352 6/20 0.41
NPC1 O15118 5/20 0.41
HPGD P15428 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 3/20 0.41
HDAC1 Q13547 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PKM P14618 1/20 0.37
RGS12 O14924 1/20 0.37
GAA P10253 1/20 0.35
EHMT2 Q96KQ7 1/20 0.35
EHMT1 Q9H9B1 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALOX15 P16050 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14157424 0.89 POLB (0.41) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL8816003 0.89 POLB (0.60) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL43414 0.88 POLB (0.41) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL2435515 0.85 POLB (0.41) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL6052790 0.83 SMN1; SMN2 (0.40) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL1888896 0.83 ALDH1A1 (0.37) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL8328957 0.83 ALDH1A1 (0.39) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL1746858 0.82 ALDH1A1 (0.35) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL2050169 0.80 POLB (0.35) POLBRAB9AALDH1A1NPC1HPGD
SCHEMBL12092095 0.79 LMNA (0.42) POLBRAB9AALDH1A1NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 622 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150293106-A1 DIAROMATIC AMINO ACID SUBSTRATE FOR CATHEPSIN DETECTION INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2015-10-15 US claimed
EP-1813614-B1 Cytotoxic agents comprising new tomaymycin derivatives SANOFI SA (FR) 2011-10-05 EP claimed
US-20110160126-A1 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders OSPREY PHARMACEUTICALS LIMITED (CA) 2011-06-30 US claimed
US-7514078-B2 Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies CORNELL RESEARCH FOUNDATION, INC. (US) 2009-04-07 US claimed
US-7166702-B1 Cytotoxic conjugates comprising a chemokine receptor targeting agent OSPREY PHARMACEUTICALS, LTD. (CA) 2007-01-23 US claimed
EP-1346731-B1 Conjugates for treating inflammatory disorders and associated tissue damage OSPREY PHARMACEUTICALS LTD (CA) 2006-12-06 EP claimed
US-20060198820-A1 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders OSPREY PHARMACEUTICALS LIMITED (CA) 2006-09-07 US claimed
EP-0832201-B1 A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY UNIV ARIZONA (US) 2005-10-05 EP claimed
US-6924268-B2 Method for inactivating gonadotrophs COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2005-08-02 US claimed
EP-1346731-A1 Conjugates for treating inflammatory disorders and associated tissue damage Osprey Pharmaceuticals Limited (CA) 2003-09-24 EP claimed
EP-1098664-A2 CONJUGATES FOR TREATING INFLAMMATORY DISORDERS AND ASSOCIATED TISSUE DAMAGE Osprey Pharmaceuticals Limited (CA) 2001-05-16 EP claimed
US-6103881-A HORMONE/NUCLEASE CONJUGATE CAPABLE OF BINDING TO GONADOTROPH CELLS AND PREVENTING SECRETION OF GONADOTROPHINS; TREATMENT OF HORMONE RELATED DISORDERS SUCH AS BREAST AND PROSTATE CANCER; STERILIZATION OF ANIMALS COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2000-08-15 US claimed
US-6093541-A WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) 2000-07-25 US claimed
WO-2000021576-A2 METHOD FOR VIEWING TUMOR TISSUE LOCATED WITHIN A BODY CAVITY FLUORO PROBE, INC. (US) 2000-04-20 WO claimed
WO-2000004926-A2 CONJUGATES FOR TREATING INFLAMMATORY DISORDERS AND ASSOCIATED TISSUE DAMAGE OSPREY PHARMACEUTICALS LIMITED (CA) 2000-02-03 WO claimed
US-6004770-A MASS SPECTROMETRY SAMPLE PRESENTATION APPARATUSES DERIVATIZED WITH COMPLEXES INCLUDING AT LEAST ONE MOLECULE WHICH MODIFIES A BIOMOLECULE ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) 1999-12-21 US claimed
US-5631229-A ADMINISTERING A PEPTIDE HORMONE/TOXIN CONJUGATE WHICH SELECTIVELY BINDS TO RECEPTORS IN THE PITUITARY GLAND; ANTIFERTILITY AGENTS; STERILIZATION; SIDE EFFECT REDUCTION; CATTLE COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1997-05-20 US claimed
US-5492893-A STERILIZATION OF ANIMALS; THERAPY OD SEX HORMONE RELATEDDISEASES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1996-02-20 US claimed
US-5488036-A GONADOTROPHINS IN CELLS FOR POLYPEPTIDE HORMONES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1996-01-30 US claimed
US-5378688-A Conjugating luteinizing hormone releasing hormone to plant, bacterialo or chemical toxins COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1995-01-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150293106-A1 DIAROMATIC AMINO ACID SUBSTRATE FOR CATHEPSIN DETECTION CTSV, CTSZ, CTSH POLB 2845/4885RAB9A 1562/4885ALDH1A1 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.